Toxicogenomics - Getting Us a Step Closer Towards Personalized Medicine
作者： Kulvinder S Saini
DOI: 10.15406/JIG.2015.02.00024
关键词:
摘要: Submit Manuscript | http://medcraveonline.com J Investig Genomics 2015, 2(3): 00024 week against specific targets and therapeutic areas. From new drug discovery research (NDDR) point of view, one the unprecedented challenges facing pharmaceutical industry is constant failure its promising molecules during clinical development. Almost half these lead candidates will have toxicity related issues. Hepatic, cardiac, muscle renal tissues are most vulnerable to drug-induced collectively contribute over 80% withdrawn from development sometimes even after launch. This necessitates identification compounds, with potential side-effects, early in process replacing them innovative better backup molecules, thereby saving resources precious time for industry.
medcraveonline.com参考文章(10)
Deepika Singh, Akriti Kashyap, Ram Vinay Pandey, Kulvinder Singh Saini, Novel advances in cytochrome P450 research Drug Discovery Today. ,vol. 16, pp. 793- 799 ,(2011) , 10.1016/J.DRUDIS.2011.08.003
Priyanka Priyadarsiny, Sunil K. Khattar, Renu Malik, Venkatesha Udupa, Arigila Seshaiah, Shamsur Rahman, Vyas Madhavrao Shingatgeri, Roop Singh Bora, Kulvinder Singh Saini, Differential gene expression analysis of a known hepatotoxin, N-acetyl-p-amino-phenol (APAP) as compared to its non-toxic analog, N-acetyl-m-amino-phenol (AMAP) in mouse liver. Journal of Toxicological Sciences. ,vol. 33, pp. 163- 173 ,(2008) , 10.2131/JTS.33.163
Anurag Mathur, Peter Loskill, Kaifeng Shao, Nathaniel Huebsch, SoonGweon Hong, Sivan G. Marcus, Natalie Marks, Mohammad Mandegar, Bruce R. Conklin, Luke P. Lee, Kevin E. Healy, Human iPSC-based cardiac microphysiological system for drug screening applications. Scientific Reports. ,vol. 5, pp. 8883- 8883 ,(2015) , 10.1038/SREP08883
Saifur R. Khan, Argishti Baghdasarian, Richard P. Fahlman, Karim Michail, Arno G. Siraki, Current status and future prospects of toxicogenomics in drug discovery Drug Discovery Today. ,vol. 19, pp. 562- 578 ,(2014) , 10.1016/J.DRUDIS.2013.11.001
Jane J. Pappas, Phillip C. Yang, Human ESC vs. iPSC-pros and cons. Journal of Cardiovascular Translational Research. ,vol. 1, pp. 96- 99 ,(2008) , 10.1007/S12265-008-9032-2
Kedar Purnapatre, Sunil K. Khattar, Kulvinder Singh Saini, Cytochrome P450s in the development of target-based anticancer drugs Cancer Letters. ,vol. 259, pp. 1- 15 ,(2008) , 10.1016/J.CANLET.2007.10.024
Johannes Eichner, Clemens Wrzodek, Michael Römer, Heidrun Ellinger-Ziegelbauer, Andreas Zell, Evaluation of Toxicogenomics Approaches for Assessing the Risk of Nongenotoxic Carcinogenicity in Rat Liver PLoS ONE. ,vol. 9, pp. e97678- ,(2014) , 10.1371/JOURNAL.PONE.0097678
Jamal Sabir, Osama Abu-Zinadah, Roop Bora, Mohamed Ahmed, Kulvinder Saini, Role of toxicogenomics in the development of safe, efficacious and novel anti-microbial therapies. Infectious disorders drug targets. ,vol. 13, pp. 206- 214 ,(2013) , 10.2174/1871526511313030009
Minjun Chen, Min Zhang, Jürgen Borlak, Weida Tong, A Decade of Toxicogenomic Research and Its Contribution to Toxicological Science Toxicological Sciences. ,vol. 130, pp. 217- 228 ,(2012) , 10.1093/TOXSCI/KFS223
Felicia W. Pagliuca, Jeffrey R. Millman, Mads Gürtler, Michael Segel, Alana Van Dervort, Jennifer Hyoje Ryu, Quinn P. Peterson, Dale Greiner, Douglas A. Melton, Generation of Functional Human Pancreatic β Cells In Vitro Cell. ,vol. 159, pp. 428- 439 ,(2014) , 10.1016/J.CELL.2014.09.040